Navigation Links
Schering-Plough Announces Organizational Changes at Schering-Plough Research Institute
Date:2/8/2008

KENILWORTH, N.J., Feb. 8 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today announced leadership and organizational changes at Schering-Plough Research Institute (SPRI), the research and development arm of Schering-Plough.

Jacqueline Elbonne, Ph.D., has been named vice president, Global Research Quality, SPRI, effective immediately. In this position, Elbonne will build and lead a worldwide research quality team overseeing all SPRI activities governed by current Good Manufacturing Practices, Good Laboratory Practices, Good Clinical Practices and Good Pharmacovigilance Practices. In addition, she will direct and govern the design, implementation and performance management of global research Quality Management Systems to meet regulatory requirements and expectations worldwide. Elbonne will report directly to Thomas P. Koestler, Ph.D., executive vice president and president of SPRI, with shared accountability for SPRI quality systems to Richard S. Bowles III, senior vice president, Global Quality Operations.

Elbonne joined Schering-Plough in 2000 and has since held various positions of increasing responsibility in SPRI, Analytical Development and Global Quality. She recently served as vice president, Pharmaceutical Sciences Quality, providing quality leadership overseeing global clinical manufacturing operations, which included meeting all commitments under the U.S. consent decree. She earned a Ph.D. in organic chemistry and a Bachelor of Science degree in chemistry and pharmacology from the University of Liverpool, England.

The following new positions were created in response to the company's expanded product portfolio following the acquisition of Organon BioSciences. Effective immediately, Martin H. Huber, Jr., M.D., and Hans Rekers, M.D., will report to Robert J. Spiegel, M.D., chief medical officer and senior vice president. Huber is appointed vice president, Global Pharmacovigilance, and deputy chief medical officer. In this role, he will continue his current responsibilities and additionally will serve on Schering-Plough's Safety Review Board. He will also interact on product-related issues with health authorities and professional societies, manage medical aspects of litigation issues and work with medical directors from country operations on risk management and product-specific issues.

Huber has served as vice president, Global Pharmacovigilance, since joining Schering-Plough in July of 2006. He has played a key role in the development of a globally-aligned organization for Global Pharmacovigilance as part of Schering-Plough's Global Clinical Harmonization program and on the design and rollout of a rigorous computerized system for the collection, tracking and reporting of drug safety information. Huber received an M.D. degree from Baylor College of Medicine and a Bachelor of Science degree from Texas Lutheran College.

Hans Rekers, M.D., is appointed deputy chief medical officer for Europe. In this role, Rekers will continue his current responsibilities and additionally will serve on Schering-Plough's Safety Review Board and on the company's PReP (preparedness response) team. He will also interact on product- related issues with worldwide health authorities and professional societies, manage medical aspects of litigation issues and work with medical directors from country operations on risk management and product-specific issues.

Rekers has been with Organon International for the past 20 years serving in a range of positions of increasing responsibility, most recently as vice president, Medical Affairs. In this role, he has global oversight for the gynecological product portfolio. Rekers holds an M.D. from the University of Amsterdam.

Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription and consumer products as well as to animal health products. In November 2007, Schering-Plough acquired Organon BioSciences, with its Organon human health and Intervet animal health businesses, marking a pivotal step in the company's ongoing transformation. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its approximately 50,000 people around the world. The company is based in Kenilworth, N.J., and its Web site is http://www.schering-plough.com.


'/>"/>
SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
2. Schering-Plough Announces Sugammadex New Drug Application Filed in Japan
3. Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA
4. Schering-Plough to Webcast Presentation at Morgan Stanley Pharmaceutical CEOs Unplugged Conference
5. Schering-Plough Schedules Conference Call and Webcast for 2007 Fourth Quarter, Full-Year Financial Result
6. Schering-Plough Wins Three of Scrips Top Pharma Industry Awards
7. Schering-Plough Completes Acquisition of Organon BioSciences
8. Schering-Plough Receives Approval from European Commission for Planned Acquisition of Organon BioSciences N.V.
9. Schering-Plough to Webcast Presentation at Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference
10. Schering-Plough Announces Pricing of Senior Notes Offering
11. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... , March 24, 2017 Sinovac Biotech Ltd. ("Sinovac" or ... China , today announced that its board of ... date of the plan from March 27, 2017 to March 27, ... About Sinovac Biotech Ltd. ... Sinovac Biotech Ltd. is a ...
(Date:3/23/2017)... ... ... is proud to announce it has become the premiere team-building cooking event company in San ... world, such as Illumina, HP and Qualcomm, and is ranked #1 in its category on ... to its new team building format, a way for teams to not only interact with ...
(Date:3/23/2017)...  BioPharmX Corporation (NYSE MKT: BPMX), a specialty ... today reported financial results for the quarter and ... an update on the company,s clinical development efforts ... are pleased to report that last year was ... Anja Krammer. "We achieved key clinical milestones and ...
(Date:3/23/2017)... March 23, 2017  Agriculture technology company Cool Planet ... and note conversion to commercialize its Cool Terra and ... on developing products that are simultaneously profitable as well ... the last 18 months. This latest round of funding ... Partners. The company,s primary product, Cool ...
Breaking Biology Technology:
(Date:3/1/2017)... 2017  Aware, Inc. (NASDAQ: AWRE), a leading supplier ... P. Moberg has resigned, effective March 3, 2017, ... Officer and Treasurer of Aware citing a desire to ... member of the Board of Directors of Aware. ... Officer and co-President, General Counsel has been named Chief ...
(Date:2/28/2017)... 27. Februar 2017  EyeLock LLC, ein marktführendes Unternehmen ... erstklassige biometrische Lösung zur Iris-Erkennung auf der ... LTE auf dem Mobile World Congress 2017 ... in Halle 3, Stand 3E10, vorstellen. ... Qualcomm Haven™ – eine Kombination aus Hardware, ...
(Date:2/24/2017)...  EyeLock LLC, a leader of iris-based identity ... biometric solution on the latest Qualcomm® Snapdragon™ 835 ... World Congress 2017 (February 27 – March ... 3, Stand 3E10. The Snapdragon ... platform—a combination of hardware, software and biometrics ...
Breaking Biology News(10 mins):